Kidney Cancer: Pathology: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) No edit summary |
||
| Line 157: | Line 157: | ||
*** Exceptions include chromophobe, collecting duct, and medullary RCC (see below) | *** Exceptions include chromophobe, collecting duct, and medullary RCC (see below) | ||
=== | === <span style="color:#ff0000">Subtypes</span> === | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''<span style="color:#ff0000">Histology</span>''' | |'''<span style="color:#ff0000">Histology</span>''' | ||
| Line 216: | Line 216: | ||
'''<span style="color:#ff0000">Generally good prognosis</span>''', compared to clear cell and papillary | '''<span style="color:#ff0000">Generally good prognosis</span>''', compared to clear cell and papillary | ||
* Rates of disease-specific (recurrence, metastasis, or death due disease) events following nephrectomy: | * Rates of disease-specific (recurrence, metastasis, or death due disease) events following nephrectomy:[https://pubmed.ncbi.nlm.nih.gov/21602658/] | ||
** 5 years: 3.7% | ** 5 years: 3.7% | ||
** 10 years: 6.4% | ** 10 years: 6.4% | ||
* Features associated with disease-specific events (4): | * Features associated with disease-specific events (4):[https://pubmed.ncbi.nlm.nih.gov/21602658/] | ||
*# Tumour size | *# Tumour size | ||
*# Small-vessel invasion | *# Small-vessel invasion | ||
| Line 276: | Line 276: | ||
|} | |} | ||
=== | === <span style="color:#ff0000">Other histologic features</span> === | ||
* '''<span style="color:#ff0000">Sarcomatoid differentiation</span>''' | * '''<span style="color:#ff0000">Sarcomatoid differentiation</span>''' | ||